Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dynamic BH3 profiling-poking cancer cells with a stick.

Literature DB >> 27314085

Dynamic BH3 profiling-poking cancer cells with a stick.

Abstract

The vast majority of efforts in precision medicine for cancer try to link static genetic information to tumor biology and from there predict clinical response. Dynamic BH3 profiling offers an alternative functional approach by measuring death signaling induced by specific drugs in tumors from patients ex vivo to predict clinical response.

Entities: Chemical Disease Species

Year: 2016 PMID： 27314085 PMCID： PMC4909438 DOI： 10.1080/23723556.2015.1040144

Source DB: PubMed Journal: Mol Cell Oncol ISSN： 2372-3556

10 in total

1. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.

Authors: Joan Montero; Kristopher A Sarosiek; Joseph D DeAngelo; Ophélia Maertens; Jeremy Ryan; Dalia Ercan; Huiying Piao; Neil S Horowitz; Ross S Berkowitz; Ursula Matulonis; Pasi A Jänne; Philip C Amrein; Karen Cichowski; Ronny Drapkin; Anthony Letai
Journal: Cell Date: 2015-02-26 Impact factor: 41.582

2. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.

Authors: Michael Certo; Victoria Del Gaizo Moore; Mari Nishino; Guo Wei; Stanley Korsmeyer; Scott A Armstrong; Anthony Letai
Journal: Cancer Cell Date: 2006-05 Impact factor: 31.743

3. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.

Authors: Triona Ni Chonghaile; Kristopher A Sarosiek; Thanh-Trang Vo; Jeremy A Ryan; Anupama Tammareddi; Victoria Del Gaizo Moore; Jing Deng; Kenneth C Anderson; Paul Richardson; Yu-Tzu Tai; Constantine S Mitsiades; Ursula A Matulonis; Ronny Drapkin; Richard Stone; Daniel J Deangelo; David J McConkey; Stephen E Sallan; Lewis Silverman; Michelle S Hirsch; Daniel Ruben Carrasco; Anthony Letai
Journal: Science Date: 2011-10-27 Impact factor: 47.728

4. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.

Authors: Thanh-Trang Vo; Jeremy Ryan; Ruben Carrasco; Donna Neuberg; Derrick J Rossi; Richard M Stone; Daniel J Deangelo; Mark G Frattini; Anthony Letai
Journal: Cell Date: 2012-10-12 Impact factor: 41.582

5. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors: J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal: Science Date: 2004-04-29 Impact factor: 47.728

6. BH3 profiling in whole cells by fluorimeter or FACS.

Authors: Jeremy Ryan; Anthony Letai
Journal: Methods Date: 2013-04-20 Impact factor: 3.608

7. The scientific drunk and the lamppost: massive sequencing efforts in cancer discovery and treatment.

Authors: Michael B Yaffe
Journal: Sci Signal Date: 2013-04-02 Impact factor: 8.192

Review 8. Circumventing cancer drug resistance in the era of personalized medicine.

Authors: Levi A Garraway; Pasi A Jänne
Journal: Cancer Discov Date: 2012-02-28 Impact factor: 39.397

9. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Authors: Gideon Bollag; Peter Hirth; James Tsai; Jiazhong Zhang; Prabha N Ibrahim; Hanna Cho; Wayne Spevak; Chao Zhang; Ying Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Garson Tsang; Brian L West; Ben Powell; Rafe Shellooe; Adhirai Marimuthu; Hoa Nguyen; Kam Y J Zhang; Dean R Artis; Joseph Schlessinger; Fei Su; Brian Higgins; Raman Iyer; Kurt D'Andrea; Astrid Koehler; Michael Stumm; Paul S Lin; Richard J Lee; Joseph Grippo; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Paul B Chapman; Keith T Flaherty; Xiaowei Xu; Katherine L Nathanson; Keith Nolop
Journal: Nature Date: 2010-09-30 Impact factor: 49.962

10. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Authors: Jordi Barretina; Giordano Caponigro; Nicolas Stransky; Kavitha Venkatesan; Adam A Margolin; Sungjoon Kim; Christopher J Wilson; Joseph Lehár; Gregory V Kryukov; Dmitriy Sonkin; Anupama Reddy; Manway Liu; Lauren Murray; Michael F Berger; John E Monahan; Paula Morais; Jodi Meltzer; Adam Korejwa; Judit Jané-Valbuena; Felipa A Mapa; Joseph Thibault; Eva Bric-Furlong; Pichai Raman; Aaron Shipway; Ingo H Engels; Jill Cheng; Guoying K Yu; Jianjun Yu; Peter Aspesi; Melanie de Silva; Kalpana Jagtap; Michael D Jones; Li Wang; Charles Hatton; Emanuele Palescandolo; Supriya Gupta; Scott Mahan; Carrie Sougnez; Robert C Onofrio; Ted Liefeld; Laura MacConaill; Wendy Winckler; Michael Reich; Nanxin Li; Jill P Mesirov; Stacey B Gabriel; Gad Getz; Kristin Ardlie; Vivien Chan; Vic E Myer; Barbara L Weber; Jeff Porter; Markus Warmuth; Peter Finan; Jennifer L Harris; Matthew Meyerson; Todd R Golub; Michael P Morrissey; William R Sellers; Robert Schlegel; Levi A Garraway
Journal: Nature Date: 2012-03-28 Impact factor: 49.962

10 in total

14 in total

Review 1. A connection in life and death: The BCL-2 family coordinates mitochondrial network dynamics and stem cell fate.

Authors: Megan L Rasmussen; Vivian Gama
Journal: Int Rev Cell Mol Biol Date: 2020-01-27 Impact factor: 6.813

2. Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.

Authors: Raphael Koch; Amanda L Christie; Jennifer L Crombie; Adam C Palmer; Deborah Plana; Kay Shigemori; Sara N Morrow; Alexandria Van Scoyk; Wenchao Wu; Elizabeth A Brem; J Paul Secrist; Lisa Drew; Alwin G Schuller; Justin Cidado; Anthony Letai; David M Weinstock
Journal: Blood Date: 2018-11-29 Impact factor: 22.113

3. Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts.

Authors: Rita Fior; Vanda Póvoa; Raquel V Mendes; Tânia Carvalho; António Gomes; Nuno Figueiredo; Miguel Godinho Ferreira
Journal: Proc Natl Acad Sci U S A Date: 2017-08-23 Impact factor: 11.205

Review 4. Targeting minimal residual disease: a path to cure?

Authors: Marlise R Luskin; Mark A Murakami; Scott R Manalis; David M Weinstock
Journal: Nat Rev Cancer Date: 2018-01-29 Impact factor: 60.716

Review 5. Targeting MCL-1 in hematologic malignancies: Rationale and progress.

Authors: Andrew H Wei; Andrew W Roberts; Andrew Spencer; Aaron Seth Rosenberg; David Siegel; Roland B Walter; Sean Caenepeel; Paul Hughes; Zach McIver; Khalid Mezzi; Phuong Khanh Morrow; Anthony Stein
Journal: Blood Rev Date: 2020-02-21 Impact factor: 8.250

6. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.

Authors: Haley E Ramsey; Melissa A Fischer; Taekyu Lee; Agnieszka E Gorska; Maria Pia Arrate; Londa Fuller; Kelli L Boyd; Stephen A Strickland; John Sensintaffar; Leah J Hogdal; Gregory D Ayers; Edward T Olejniczak; Stephen W Fesik; Michael R Savona
Journal: Cancer Discov Date: 2018-09-05 Impact factor: 39.397

7. hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents.

Authors: Elisa Barile; Guya D Marconi; Surya K De; Carlo Baggio; Luca Gambini; Ahmed F Salem; Manoj K Kashyap; Januario E Castro; Thomas J Kipps; Maurizio Pellecchia
Journal: ACS Chem Biol Date: 2016-12-27 Impact factor: 5.100